Teva share price hits nearly 10-year high

Teva Pharmaceutical Industries' share price reached a nearly 10-year high last week, closing up 1.44% on Friday with a market cap of $43.512 billion. The stock has risen 20% over the past month, driven by positive second-quarter results, a Moody's debt rating upgrade to investment grade, and FDA acceptance of Ecopipam for Tourette's syndrome.

Teva Pharmaceutical Industries' share price hit a nearly 10-year high last week, closing up 1.44% on Friday with a market cap of $43.512 billion. The stock has risen 20% over the past month. Catalysts include positive Q2 financial results and raised annual revenue guidance in late July, Moody's upgrading Teva's debt rating to investment grade this month (following Fitch's earlier upgrade), and FDA acceptance of Ecopipam for Tourette's syndrome with an accelerated review and decision target by end of Q1 2027. Of 13 analysts covering Teva, 12 have positive recommendations and one is neutral, with an average price target of $42.38, reflecting a 12.3% premium to the current NYSE price.